Dimensional ETF Trust Dimensional International Vector Equity ETF (ARCA: DXIV)

Latest news for Dimensional ETF Trust Dimensional International Vector Equity ETF (ARCA:DXIV)

To achieve the International Vector Equity ETFs investment objective, Dimensional Fund Advisors LP (the Advisor) implements an integrated investment approach that combines research, portfolio design, portfolio management, and trading functions. As further described below, the Portfolios design emphasizes long-term drivers of expected returns identified by the Advisors research, while balancing risk through broad diversification across companies and sectors. The Advisors portfolio management and trading processes further balance those long-term drivers of expected returns with shorter-term drivers of expected returns and trading costs

Dimensional International Vector Equity ETF

Dimensional ETF Trust Dimensional International Vector Equity ETF

Franklin Templeton, a multi-trillion dollar asset management firm, has filed for a new <a href="https://www.benzinga.com/money/best-spot-bitcoin-etfs">exchange-traded fund</a> (ETF) that would provide exposure to both Bitcoin and Ethereum.
According to an application with the U.S. Securities and Exchange Commission (SEC) on Wednesday, the firm <a href="https://www.sec.gov/files/rules/sro/cboebzx/2024/34-101233.pdf">aims</a> to offer investors a single product that tracks the performance of the two largest cryptocurrencies by market capitalization.
<h3 class="wp-block-heading">A New Index ETF On The Horizon</h3>
The Oct. 2 filing reveals Franklin Templeton&#8217;s intention to launch an index fund that encompasses both Bitcoin and Ethereum. An index fund typically tracks the performance of a collection of assets—such as stocks, bonds, or cryptocurrencies—enabling investors to gain exposure to these assets without directly owning them. 
In this case, the proposed ETF would specifically target Bitcoin and Ethereum, allowing investors to benefit from the movement of these leading cryptocurrencies.
If approved, the new Franklin Templeton Bitcoin and Ethereum Crypto Index ETF will be traded on the Chicago Board Options Exchange (BATS:<a class="ticker" href="https://www.benzinga.com/stock/CBOE#BATS">CBOE</a>).
Bank of New York Mellon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BK#NYSE">BK</a>), one of the largest custodians in the United States, is set to handle the fund&#8217;s cash and cash equivalents, while Coinbase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) will act as the custodian for the Bitcoin and Ethereum tokens within the fund.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41163889/save-ross-ulbricht-how-donald-trump-got-interested-in-the-imprisoned-silk-road-founder">&#8216;Save Ross Ulbricht!&#8217; How Donald Trump Got Interested In The Imprisoned Silk Road Founder</a>
A notable aspect of this offering is that the fund will be sold in large increments, specifically in blocks of 50,000 shares. 
The product's Net Asset Value (NAV) will be used to determine the share price. Additionally, the index fund will be benchmarked against the CF Institutional Digital Asset Index, which tracks the market performance of both Bitcoin and Ethereum.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/27091545/Benzinga-conference.gif" alt="Benzinga future of digital assets conference" class="wp-image-267246" /></a></figure>
<h3 class="wp-block-heading">Expanding Franklin Templeton&#8217;s Crypto Reach</h3>
This filing marks a potential expansion of Franklin Templeton's involvement in the cryptocurrency space. 
The asset manager already provides clients with exposure to spot Bitcoin and <a href="https://www.benzinga.com/money/what-is-ethereum-etf#:~:text=A%20Spot%20Ethereum%20ETF%20could,stable%20prices%20and%20reduced%20volatility.">Ethereum ETFs</a>, highlighting its ongoing interest in broadening its crypto-based offerings.
Interestingly, this ETF filing comes just hours after Franklin Templeton announced a collaboration with the Aptos Foundation to launch its on-chain U.S. Government Money Market Funds (FOBXX). 
This product gives investors access to FOBXX through the purchase of the BENJI (CRYPTO: BENJI) token, showcasing the firm's diversified approach to integrating blockchain technology into traditional finance products.
<h3 class="wp-block-heading">BNY Mellon&#8217;s Role In The ETF</h3>
Bank of New York Mellon is poised to play a significant role in this potential ETF, as the institution will receive its first ETF custody duties following a non-objection letter from the SEC.
This regulatory clearance allows BNY Mellon to hold digital assets, with an initial focus on Bitcoin and Ethereum ETFs. 
While this exemption was granted with certain conditions, SEC Chairman Gary Gensler has indicated that BNY Mellon could expand its digital asset custody services if it adheres to specific guidelines.
For those interested in the intersection of traditional finance and digital assets, Benzinga's <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> event on November 19 will provide further insights and discussions with industry experts.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41161014/trump-vs-harris-who-do-voters-trust-more-to-handle-crypto-policies">Trump Vs. Harris: Who Do Voters Trust More To Handle Crypto Policies?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

CBOE

COIN

Franklin Templeton Seeks SEC Approval For Dual Bitcoin, Ethereum Index ETF

AUD/NZD is one I'm looking at for an RBA/RBNZ play.
We've seen the kiwi side weakening as lots of banks are calling a 50bp cut at the RBNZ meeting next week (9th October).
There's pros and cons to those calls.
Pro's Their rate is still relatively high vs everyone else (5.25%). Inflation is back at target. They noted weakening economic factors.
Cons The RBNZ have said they will take a "careful and measured" approach to cuts They want to stay restrictive to keep inflation expectations where they are, and that's their "single focus". They say there's still things pointing to positive econ growth, so they feel cuts are more to "remove restraint than provide stimulus".
Overall, the RBNZ haven't come across more dovish to an extent that would lead them to 50bp cuts, and I'm thinking the market may be getting a bit too dovish.
But, this is central banking so no one is going to rule a 50bp cut out after the Fed.
For the trade set up, these expectations for a 50 are being priced in so there's a positive for the trade risk in that If a 50 is expected, a 50 won't be a shock if they drop one. That favours my thinking for being short AUDNZD. On the RBA side, I still hold the view that they will be forced to cut sooner than they think and are telling everyone. We've already had one shift of pushing a hike further away, the next will be data pointing to them cutting. There may be a Bailey styled flip in the pipeline (probably not soon though).
My plan is to get in short AUDNZD and run it over the RNBZ. If the market is expecting 50 and they go a 25, that should get the trade off to a good start and then perhaps I can stay in it to catch an RBA turn.
Obviously lots can happen between events, and AUD is likely to remain strong while the China hopium trade continues.
I'd like AUDNZD a bit higher to start getting in. Ideally up near the last highs around 1.1150's would look tempting, otherwise I might start nibbling small pieces around this 1.10-1.1050 area.<a href="https://www.forexanalytix.com/blog/wp-content/uploads/2024/10/AUDNZD_2024-10-03_14-16-18.png"></a>
There's obvious risks that they have seen a material change in the economy and inflation indicators since their last meeting, and they could well come out far more dovish. That's a risk I'll factor into my trading risk parameters and trade management. If I'm wrong, I'll be wrong on my terms. Like all my trades, I'll be focused on the risk before I focus on any profit.
Ryan Littlestone
Forex Analytix 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="618" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/03151136/AUDNZD_2024-10-03_14-16-18-1024x618.png" alt="" class="wp-image-1852" style="width:624px" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/03151136/AUDNZD_2024-10-03_14-16-18-1024x618.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/03151136/AUDNZD_2024-10-03_14-16-18-300x181.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/03151136/AUDNZD_2024-10-03_14-16-18-768x463.png 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/03151136/AUDNZD_2024-10-03_14-16-18.png 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>

Markets

Trading Ideas

General

How Will AUD/NZD Trade On A 25bp Or 50bp Rate Cut From The RBNZ?

On Thursday, the FDA accepted and granted Priority Review to AstraZeneca Plc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) supplemental marketing application for Calquence (acalabrutinib) for adult patients with previously untreated <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/b41160742/calquence-acalabrutinib-granted-priority-review-in-the-us-for-patients-with-untreated-mantle-cell-" rel="noreferrer noopener">mantle cell lymphoma (MCL)</a>.
The Prescription Drug User Fee Act date, the FDA action date for their regulatory decision, is anticipated during the first quarter of 2025.
MCL is a rare and typically aggressive form of non-Hodgkin lymphoma (NHL), resulting when B-lymphocytes mutate into malignant cells within a region of the lymph node known as the mantle zone.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41050339/astrazenecas-top-selling-cancer-drug-tagrisso-receives-fda-green-light-for-another-lung-cancer-in" rel="noreferrer noopener">AstraZeneca&#8217;s Top-Selling Cancer Drug Tagrisso Receives FDA Green Light For Another Lung Cancer Indication</a>.
It is estimated that more than 27,500 people are living with MCL worldwide.
Results from the <a target="_blank" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.astrazeneca-us.com%2Fmedia%2Fpress-releases%2F2024%2Fcalquence-acalabrutinib-plus-chemoimmunotherapy-reduced-the-risk-of-disease-progression-or-death-by-27-percentage-vs-standard-of-care-in-patients-with-untreated-mantle-cell-lymphoma-in-echo-phase-iii-trial.html&amp;esheet=54130935&amp;newsitemid=20241003958806&amp;lan=en-US&amp;anchor=ECHO+Phase+III+trial&amp;index=1&amp;md5=3837bcbd9ded15f0ec3b2c2476b8d102" rel="noreferrer noopener">ECHO Phase III trial</a> recently were presented during the late-breaking oral session at the European Hematology Association (EHA) 2024 Hybrid Congress.
In the trial, Calquence plus bendamustine and rituximab reduced the risk of disease progression or death by 27% compared to standard-of-care (SoC) chemoimmunotherapy.
Adding Calquence to SoC provided almost 1.5 years of additional median progression-free survival (mPFS) with mPFS of 66.4 months for patients treated with the Calquence combination versus 49.6 months with SoC.
Overall survival (OS) showed a favorable trend for the Calquence combination compared to SoC chemoimmunotherapy.
The OS data were not mature during this analysis, and the trial will continue to assess OS as a key secondary endpoint.
The ECHO trial was conducted during the COVID-19 pandemic. After censoring COVID-19 deaths, the PFS was further improved in both arms, with the CALQUENCE combination reducing the risk of disease progression or death by 36%. A favorable trend was seen for OS in this analysis for the Calquence combination, but OS data were not mature.
Price Action: AZN stock is down 1.73% at $78.21 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41170239/american-tower-boosts-data-power-new-400g-aws-connections-to-fuel-ai-and-big-data-at-key-us-data" target="_blank" rel="noreferrer noopener">American Tower Boosts Data Power: New 400G AWS Connections To Fuel AI And Big Data At Key US Data Centers</a>.</li>
</ul>

Biotech

Large Cap

Health Care

AstraZeneca Seeks Expanded Use For Blood Cancer Drug Calquence, FDA Grants Priority Review

Philadelphia's own Gillie Da King has officially made his mark on the Pennsylvania cannabis market with the launch of Gillie Grows by Insa. Since its debut on September 27, the exclusive line of cannabis strains has captivated consumers at Restore Dispensaries and is now expanding to additional retailers across the state.
Gillie Da King, a prominent influencer and cannabis connoisseur, partnered with Massachusetts-based cannabis brand Insa to develop three unique strains: Purp 30, Mule Kick and Gillie W'nka. Each strain reflects Gillie's personal taste and dedication to high-quality cannabis, combining distinctive flavors, aromas, and effects for an exceptional user experience.
<h2 class="wp-block-heading">Gillie's Personal Touch On Every Strain</h2>
For Gillie Da King, the opportunity to create a line of cannabis strains was a dream come true. "Having the opportunity to put my personal touch on the conceptualization of these strains was a dream! These strains are top-notch, just like everything Insa cultivates in Pennsylvania. Trust me, the people are going to love it!&#8221; he shared.
The strains are a product of close collaboration with Insa's head grower, Kevin Sparks, who praised the partnership: "We combined our expertise and passion to develop these unique strains. From the handpicked terpenes and flavors to the effects Gillie loves, every detail was crafted to deliver a cannabis experience that matches exactly what Gillie looks for in his favorite strains."
<h2 class="wp-block-heading">The Three Strains: Purp 30, Mule Kick And Gillie W'nka</h2>
The Gillie Grows by Insa line includes:
<ul>
<li>Mule Kick: A hybrid with sweet and sour fruit flavors and a hint of diesel, offering balanced effects that help patients relax without feeling overly tired.</li>
<li>Purp 30: An indica-leaning hybrid featuring creamy grape and earthy gas flavors, providing relaxation for any time of day.</li>
<li>Gillie W'nka: A fruity and creamy hybrid designed for a smooth, relaxing experience that patients have praised for managing anxiety and chronic pain.</li>
</ul>
<h2 class="wp-block-heading">A Partnership Built On Loyalty And Expertise</h2>
Gillie's relationship with Restore Dispensaries made the partnership a natural fit, according to Taylor Shields, director of marketing for Restore. "Gillie has been a longtime patient of Restore, and we're honored to be the first retailer to showcase his unique product line. As an independently owned dispensary group, it's important to us that we work with loyal partners like Insa, whose mission aligns with ours."
The exclusive Gillie Grows by Insa strains continue to roll out to additional retailers across Pennsylvania, with cannabis enthusiasts and medical patients eager to experience the new products.
This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Cannabis

Retail Sales

Rapper Gillie Da King Launches Exclusive Cannabis Strains: Here's Where To Find Them

On Thursday, Visa Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) announced its new Visa Tokenized Asset Platform (VTAP). It is designed to help financial institutions issue and manage fiat-backed tokens on blockchain networks, <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/b41162006/visa-introduces-the-visa-tokenized-asset-platform" rel="noreferrer noopener">bridging existing fiat currencies with blockchain technology.</a>
BBVA has been testing core VTAP functionalities this year, including issuing, transferring, and redeeming a bank token on a testnet blockchain. They aim to launch an initial pilot with select customers on the public Ethereum blockchain in 2025.
&#8220;Visa has been at the forefront of digital payments for nearly sixty years, and with the introduction of VTAP, we are once again setting the pace for the industry,&#8221; said Vanessa Colella, Global Head of Innovation and Digital Partnerships of Visa.
Visa&#8217;s VTAP allows banks to safely and efficiently bring fiat currencies onto blockchain networks.
Also Read:<a target="_blank" href="https://www.benzinga.com/markets/cryptocurrency/24/10/41122002/playbux-ceo-envisions-web3-future-where-crypto-is-earned-via-gaming-shopping" rel="noreferrer noopener"> Playbux CEO Envisions Web3 Future Where Crypto Is Earned Via Gaming, Shopping</a>
It offers easy integration with minimal technical setup through accessible APIs, enabling banks to mint and transfer fiat-backed tokens.
VTAP supports programmability, allowing banks to use smart contracts to automate workflows and transactions.
Additionally, it promotes interoperability across various blockchains, facilitating secure cross-chain exchanges of tokenized real-world assets.
&#8220;This collaboration marks a significant milestone in our exploration of the potential of blockchain technology and will ultimately help enable us to broaden our banking services and expand the market with new financial solutions,&#8221; said Francisco Maroto, Head of Blockchain and Digital Assets, BBVA.
Price Action: V shares are trading lower by 0.26% to $276.69 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/41060712/trump-wants-nancy-pelosi-prosecuted-over-husband-pauls-visa-stock-sale-before-doj-lawsuit-you-th" target="_blank" rel="noreferrer noopener">Trump Wants Nancy Pelosi Prosecuted Over Husband Paul&#8217;s Visa Stock Sale Before DOJ Lawsuit: &#8216;You Think It Was Luck? I Don&#8217;t Think So&#8217;</a></li>
</ul>
Photo via Shutterstock

Equities

Movers

Visa Teams Up with BBVA To Issue Fiat-Backed Tokens On Blockchain Networks, Plans Initial Pilot By 2025

Citigroup analyst Ronald Josey maintains Carvana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) with a Neutral and raises the price target from $125 to $195.

Price Target

Analyst Ratings

CVNA

Citigroup Maintains Neutral on Carvana, Raises Price Target to $195

CrowdStrike Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) shares are trading higher on Thursday. The company disclosed an expansion of the CrowdStrike Marketplace, a hub for top-tier security products compatible with CrowdStrike.
This move enhances the Marketplace Private Offer program, allowing solution providers to engage with CrowdStrike Falcon-integrated technologies.
The Marketplace enables customers to easily discover, try, and purchase leading solutions from their preferred partners while integrating more cybersecurity solutions with the CrowdStrike Falcon platform.
CrowdStrike Marketplace, which was initially launched in the third-quarter of 2023, helps customers optimize cybersecurity investments and enhance the Falcon platform.
Daniel Bernard, chief business officer, CrowdStrike said, &#8220;Over the last year, the Marketplace has taken flight, aligning our entire ecosystem from ISV to solution providers and resellers around CrowdStrike customers with Falcon-integrated solutions that support our mission to stop breaches.&#8221;
&#8220;With the addition of top global and national resellers, we&#8217;re expanding access to leading ISVs, strengthening the Marketplace&#8217;s role in aligning the cybersecurity ecosystem around customer success.&#8221;
Last month, CrowdStrike launched AI Security Posture Management and Data Security Posture Management, <a target="_blank" href="https://www.benzinga.com/markets/equities/24/09/40925721/crowdstrike-launches-ai-security-posture-management-to-enhance-cloud-protection" rel="noreferrer noopener">enhancing its Falcon Cloud Security platform</a>.
Also,&nbsp;the company disclosed a partnership with&nbsp;Dazz to strengthen visibility and protection within CrowdStrike Falcon Cloud Security by <a target="_blank" href="https://www.benzinga.com/markets/equities/24/09/40915550/crowdstrike-partners-with-dazz-to-streamline-cloud-security-launches-financial-services-subsidia" rel="noreferrer noopener">incorporating&nbsp;Dazz&#8217;s security remediation insights</a>.
Investors can gain exposure to the stock via&nbsp;TrueShares Technology, AI &amp; Deep Learning ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LRNZ#NYSE">LRNZ</a>), and&nbsp;REX AI Equity Premium Income ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIPI#NYSE">AIPI</a>).
Price Action: CRWD shares are up 1.31% at $283.92 at the last check Thursday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/41016947/crowdstrike-executive-struck-by-regret-in-house-hearing-says-company-determined-to-prevent-instances" target="_blank" rel="noreferrer noopener">CrowdStrike Executive Struck By Regret In House Hearing, Says Company Determined To Prevent Instances Like Microsoft Outage From Repeating: &#8216;Deeply Sorry This Happened&#8217;</a></li>
</ul>

AIPI

CRWD

LRNZ

CrowdStrike Expands Marketplace, Falcon-Integrated Solutions Boost Cybersecurity Ecosystem

Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on Levi Strauss (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEVI#NYSE">LEVI</a>) in the last three months.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Levi Strauss, revealing an average target of $24.33, a high estimate of $26.00, and a low estimate of $21.00. A 3.34% drop is evident in the current average compared to the previous average price target of $25.17. 
<img src="https://www.benzinga.com/files/images/story/2024/1727978514_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Levi Strauss among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Boss</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$21.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Oliver Chen</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$23.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$26.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Drew Crum</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$25.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Oliver Chen</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$25.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$26.00</td>
<td>$26.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Levi Strauss. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Levi Strauss compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Levi Strauss's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Levi Strauss's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/LEVI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Levi Strauss analyst ratings.</a>
<h2>About Levi Strauss</h2>
Levi Strauss &amp; Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss &amp; Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver; Europe; and Asia.
<h3>Levi Strauss: Delving into Financials</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Levi Strauss's remarkable performance in 3 months is evident. As of 31 May, 2024, the company achieved an impressive revenue growth rate of 7.81%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Levi Strauss's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.25% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Levi Strauss's ROE stands out, surpassing industry averages. With an impressive ROE of 0.92%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Levi Strauss's ROA stands out, surpassing industry averages. With an impressive ROA of 0.3%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.12.
<h2>How Are Analyst Ratings Determined?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LEVI

Analyst Scoreboard: 6 Ratings For Levi Strauss

In the last three months, 11 analysts have published ratings on Riot Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>), offering a diverse range of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $17.68, with a high estimate of $23.00 and a low estimate of $9.50. This current average has decreased by 3.55% from the previous average price target of $18.33. 
<img src="https://www.benzinga.com/files/images/story/2024/1727978505_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Riot Platforms among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brett Knoblauch</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Paul Golding</td>
<td>Macquarie</td>
<td>Announces</td>
<td>Outperform</td>
<td>$15.00</td>
<td>-</td>
</tr>
<tr>
<td>Brett Knoblauch</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$23.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Reginald Smith</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$9.50</td>
<td>$12.00</td>
</tr>
<tr>
<td>John Todaro</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$14.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Brett Knoblauch</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$23.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Mike Colonnese</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$17.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Bill Papanastasiou</td>
<td>Stifel</td>
<td>Announces</td>
<td>Speculative Buy</td>
<td>$18.00</td>
<td>-</td>
</tr>
<tr>
<td>Brett Knoblauch</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$23.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>John Todaro</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$13.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Mike Colonnese</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$17.00</td>
<td>$17.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Riot Platforms. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Riot Platforms compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Capture valuable insights into Riot Platforms's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/RIOT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Riot Platforms analyst ratings.</a>
<h2>Unveiling the Story Behind Riot Platforms</h2>
Riot Platforms Inc is a vertically integrated Bitcoin mining company focused on building, supporting, and operating blockchain technologies. The company's segments include Bitcoin Mining; Data Center Hosting and Engineering. It generates maximum revenue from the Bitcoin Mining segment which generates revenue from the Bitcoin the company earns through its mining activities.
<h3>Riot Platforms: Financial Performance Dissected</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Riot Platforms's financials over 3 months reveals challenges. As of 30 June, 2024, the company experienced a decline of approximately -8.76% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: Riot Platforms's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -120.61%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Riot Platforms's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -3.34%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Riot Platforms's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -3.17%, the company may face hurdles in achieving optimal financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.01, Riot Platforms adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RIOT

The Latest Analyst Ratings For Riot Platforms

Truist Securities analyst Michael Ciarmoli maintains Albany Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIN#NYSE">AIN</a>) with a Buy and lowers the price target from $101 to $91.

Truist Securities Maintains Buy on Albany Intl, Lowers Price Target to $91

In the preceding three months, 20 analysts have released ratings for Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), presenting a wide array of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">12</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $992.05, a high estimate of $1125.00, and a low estimate of $884.00. Witnessing a positive shift, the current average has risen by 7.74% from the previous average price target of $920.74.
<img src="https://www.benzinga.com/files/images/story/2024/1727978449_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Eli Lilly. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>James Shin</td>
<td>Deutsche Bank</td>
<td>Maintains</td>
<td>Buy</td>
<td>$1025.00</td>
<td>$1025.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$885.00</td>
<td>$885.00</td>
</tr>
<tr>
<td>Chris Schott</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$1100.00</td>
<td>$1050.00</td>
</tr>
<tr>
<td>Peter Verdult</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Buy</td>
<td>$1060.00</td>
<td>-</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$885.00</td>
<td>$885.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$1106.00</td>
<td>$1106.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$885.00</td>
<td>$885.00</td>
</tr>
<tr>
<td>Seamus Fernandez</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$1030.00</td>
<td>$884.00</td>
</tr>
<tr>
<td>Kerry Holford</td>
<td>Berenberg</td>
<td>Raises</td>
<td>Buy</td>
<td>$1050.00</td>
<td>$1000.00</td>
</tr>
<tr>
<td>James Shin</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$1025.00</td>
<td>$725.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$1000.00</td>
<td>$875.00</td>
</tr>
<tr>
<td>Evan Seigerman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$1101.00</td>
<td>$1001.00</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$1125.00</td>
<td>$1000.00</td>
</tr>
<tr>
<td>Seamus Fernandez</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$884.00</td>
<td>$855.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$885.00</td>
<td>$885.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$885.00</td>
<td>$885.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$885.00</td>
<td>$885.00</td>
</tr>
<tr>
<td>Kerry Holford</td>
<td>Berenberg</td>
<td>Raises</td>
<td>Buy</td>
<td>$1000.00</td>
<td>$850.00</td>
</tr>
<tr>
<td>Chris Schott</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$1000.00</td>
<td>$900.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$1025.00</td>
<td>$913.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Eli Lilly. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Eli Lilly compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Eli Lilly's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Eli Lilly's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/LLY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Eli Lilly analyst ratings.</a>
<h2>Discovering Eli Lilly: A Closer Look</h2>
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
<h3>Eli Lilly's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Eli Lilly's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 35.98%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Eli Lilly's net margin excels beyond industry benchmarks, reaching 26.25%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Eli Lilly's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 22.5%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Eli Lilly's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.37% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Eli Lilly's debt-to-equity ratio is below the industry average. With a ratio of 2.13, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cracking The Code: Understanding Analyst Reviews For Eli Lilly

Throughout the last three months, 10 analysts have evaluated NEXTracker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXT#NASDAQ">NXT</a>), offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $58.7, with a high estimate of $66.00 and a low estimate of $46.00. This current average has decreased by 7.47% from the previous average price target of $63.44. 
<img src="https://www.benzinga.com/files/images/story/2024/1727978439_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of NEXTracker among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Christine Cho</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$47.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Julien Dumoulin-Smith</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Hold</td>
<td>$46.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Osha</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$55.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Mark Strouse</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$62.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Philip Shen</td>
<td>Roth MKM</td>
<td>Lowers</td>
<td>Buy</td>
<td>$65.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Derek Soderberg</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Jordan Levy</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$65.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Dimple Gosa</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$66.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Christine Cho</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$61.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Mark Strouse</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$65.00</td>
<td>$63.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to NEXTracker. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of NEXTracker compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for NEXTracker's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into NEXTracker's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/NXT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on NEXTracker analyst ratings.</a>
<h2>About NEXTracker</h2>
Nextracker (and its subsidiaries) is a leading provider of intelligent, integrated solar tracker and software solutions used in utility-scale and distributed generation solar projects around the world. Nextracker's products enable solar panels in utility-scale power plants to follow the sun's movement across the sky and optimize plant performance. Nextracker has operations in the United States, Mexico, Spain and other countries in Europe, India, Australia, the Middle East, Africa, and Brazil.
<h3>NEXTracker: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: NEXTracker's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 50.13%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: NEXTracker's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 16.9%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): NEXTracker's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 11.69%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): NEXTracker's ROA stands out, surpassing industry averages. With an impressive ROA of 4.73%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: NEXTracker's debt-to-equity ratio is below the industry average at 0.13, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 10 Analysts Discuss NEXTracker Stock

In the last three months, 18 analysts have published ratings on Shoals Technologies Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHLS#NASDAQ">SHLS</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Shoals Technologies Gr and provided 12-month price targets. The average target is $10.25, accompanied by a high estimate of $23.00 and a low estimate of $4.00. This current average represents a 16.6% decrease from the previous average price target of $12.29. 
<img src="https://www.benzinga.com/files/images/story/2024/1727978427_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The perception of Shoals Technologies Gr by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vikram Bagri</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$5.50</td>
<td>$5.00</td>
</tr>
<tr>
<td>Derek Soderberg</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Kashy Harrison</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$10.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Philip Shen</td>
<td>Roth MKM</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$6.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Jordan Levy</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$8.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Chris Dendrinos</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Julien Dumoulin-Smith</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Hold</td>
<td>$5.00</td>
<td>-</td>
</tr>
<tr>
<td>Christine Cho</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$7.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Donovan Schafer</td>
<td>Northland Capital Markets</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$4.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>Mark Strouse</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$19.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Jon Windham</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$9.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Jordan Levy</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$10.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Kashy Harrison</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$8.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Colin Rusch</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$12.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Jon Windham</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$12.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Christine Cho</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$10.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Mark Strouse</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$23.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Chris Dendrinos</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$13.00</td>
<td>$15.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Shoals Technologies Gr. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Shoals Technologies Gr compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Shoals Technologies Gr's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Shoals Technologies Gr's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SHLS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Shoals Technologies Gr analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About Shoals Technologies Gr</h2>
Shoals Technologies Group is a provider of electrical balance of system solutions for solar energy projects, primarily in the United States. EBOS encompasses components that are necessary to carry electric current produced by solar panels to an inverter. The products are sold principally to engineering, procurement, and construction firms that build solar energy projects.
<h3>A Deep Dive into Shoals Technologies Gr's Financials</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Challenges: Shoals Technologies Gr's revenue growth over 3 months faced difficulties. As of 30 June, 2024, the company experienced a decline of approximately -16.74%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.
Net Margin: Shoals Technologies Gr's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 11.89%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Shoals Technologies Gr's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.15% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Shoals Technologies Gr's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.46%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.27, Shoals Technologies Gr adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SHLS

Forecasting The Future: 18 Analyst Projections For Shoals Technologies Gr

In the last three months, 5 analysts have published ratings on TPG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPG#NASDAQ">TPG</a>), offering a diverse range of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $54.8, along with a high estimate of $63.00 and a low estimate of $42.00. This upward trend is evident, with the current average reflecting a 9.05% increase from the previous average price target of $50.25.
<img src="https://www.benzinga.com/files/images/story/2024/1727978410_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of TPG among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alexander Blostein</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$63.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Alexander Blostein</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$60.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Overweight</td>
<td>$60.00</td>
<td>-</td>
</tr>
<tr>
<td>Kenneth Worthington</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$49.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Bill Kirk</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$42.00</td>
<td>$44.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to TPG. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of TPG compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of TPG's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of TPG's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/TPG/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on TPG analyst ratings.</a>
<h2>About TPG</h2>
TPG Inc is an alternative asset firm. It invests across five multi-product platforms namely Capital, Growth, Impact, Real Estate, and Market Solutions. TPG aims to build dynamic products and options for its clients while also instituting discipline and operational excellence across the investment and performance of its portfolio.
<h3>Financial Insights: TPG</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining TPG's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 34.02% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Financials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: TPG's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -2.66%, the company may face hurdles in effective cost management.
Return on Equity (ROE): TPG's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -2.18%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): TPG's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -0.16%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a high debt-to-equity ratio of 1.72, TPG faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>What Are Analyst Ratings?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Navigating 5 Analyst Ratings For TPG

Morgan Stanley analyst Adam Jonas reiterates Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) with a Overweight and maintains $310 price target.

Reiteration

TSLA

Morgan Stanley Reiterates Overweight on Tesla, Maintains $310 Price Target

Citigroup analyst Scott Gruber maintains NOV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOV#NYSE">NOV</a>) with a Buy and lowers the price target from $24 to $21.

Citigroup Maintains Buy on NOV, Lowers Price Target to $21

https://ppubs.uspto.gov/pubwebapp/external.html?q=(20240325067).pn

VERO

Venus Concept Labs Has Filed A New Patent Application Titled "METHOD AND DEVICE FOR TREATING THE SKIN"

Citigroup analyst Scott Gruber maintains Liberty Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LBRT#NYSE">LBRT</a>) with a Buy and lowers the price target from $28 to $25.

LBRT

Citigroup Maintains Buy on Liberty Energy, Lowers Price Target to $25

Citigroup analyst Spiro Dounis maintains Williams Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMB#NYSE">WMB</a>) with a Buy and raises the price target from $45 to $52.

Citigroup Maintains Buy on Williams Companies, Raises Price Target to $52

Citigroup analyst Christopher Allen maintains CME Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CME#NASDAQ">CME</a>) with a Buy and raises the price target from $240 to $250.

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Comments

Dimensional ETF Trust Dimensional International Vector Equity ETF

News

Latest news for Dimensional ETF Trust Dimensional International Vector Equity ETF (ARCA:DXIV)